![Weekly Enforcement Report: A Biotech Outlier](https://www.g2intelligence.com/wp-content/uploads/2023/01/Jan11-2023.News_.WeeklyEnforcementReport.FCA-and-Kickbacks-iStock-1800x1250-1-1080x675.jpg)
Weekly Enforcement Report: A Biotech Outlier
While most recent cases were the usual FCA and kickback-related issues, one involved the mischarging of federal grants by two biotech companies and their co-founder.
While most recent cases were the usual FCA and kickback-related issues, one involved the mischarging of federal grants by two biotech companies and their co-founder.
In our latest roundup, schemes involving cancer genetic testing and kickbacks remain the most common, but there were some surprises.
Enforcement actions over our most recent coverage period were related to other areas of the healthcare industry.
Federal enforcement actions at the end of October and first two weeks of November featured some unusual characters.
On Nov. 15, a psychiatrist and clinical lab owner pled guilty to his role in a complicated $3.8 million fraud scheme.